You are here

  • Home
  • Archive
  • Volume 78, Issue 11
  • Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez
Free
  1. Dinesh Khanna1,
  2. Angelika Jahreis2,
  3. Celia J F Lin2
  1. 1 Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA
  2. 2 Product Development, Genentech, Inc, South San Francisco, California, USA
  1. Correspondence to Dr Dinesh Khanna, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA; khannad{at}med.umich.edu

https://doi.org/10.1136/annrheumdis-2018-214477

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read the intriguing findings by Narváez1 about the effect of tocilizumab (TCZ) in patients with established systemic sclerosis-associated interstitial lung disease (SSc-ILD) with great interest. In the double-blind, randomised, placebo-controlled faSScinate study2 and open-label extension,3 we assessed the efficacy and safety of TCZ in patients with systemic sclerosis. There were important differences between our trial and the data presented by Narváez1. In the faSScinate study, the patient population shown to benefit from TCZ had shorter duration of disease (mean disease duration of 1.6 years in faSScinate vs 6.9 years in Narváez), increased serum acute phase reactants, …

    View Full Text

    Linked Articles